Service Optimisation of Prostate Cancer SACT Pathway

This document is a report detailing a collaborative working project between Astellas Pharma Ltd and Portsmouth Hospitals University NHS Trust focused on the service optimisation of the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway. The project aims to conduct a service review of the Prostate Cancer Oral SACT Novel Hormone Therapy pathway from March 2025 to May 2026. The objective is to redesign the pathway to enhance the prostate cancer service at the cancer center. The report outlines the burden of new prostate cancer cases on NHS capacity and emphasizes the need for efficiency improvements within the service. It discusses the potential benefits for patients, including reduced waiting times and increased satisfaction, as well as benefits for the NHS such as improved service delivery and capacity. Additionally, it highlights the value of collaboration among Astellas, Bionical Health, and cancer centers to enhance patient well-being and service effectiveness.